AI Is Making Drug Pipelines Bigger. It Might Also Be Making Them Worse.

Lilly's $2.8 Billion Bet on Psychedelics Buys Science That Conventional Trial Infrastructure May Not Be Able to Run. July 21, 2026. Latest News.

Share this story

Surfaced by this Google Alert